Nanoviricides, Inc. financial data

Symbol
NNVC on NYSE
Industry
Pharmaceutical Preparations
Location
1 Controls Drive, Shelton, CT
State of incorporation
NV
Fiscal year end
June 30
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 375 % -76.8%
Debt-to-equity 10.7 %
Return On Equity -84.6 % -55.2%
Return On Assets -76.5 % -51.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 14.7M shares +25%
Common Stock, Shares, Outstanding 14.1M shares +19.7%
Entity Public Float 11.4M USD -7.2%
Common Stock, Value, Issued 140 USD +19.7%
Weighted Average Number of Shares Outstanding, Basic 13.7M shares +17%
Weighted Average Number of Shares Outstanding, Diluted 13.7M shares +17%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 5.9M USD -12.5%
General and Administrative Expense 3.75M USD +43.8%
Operating Income (Loss) -9.65M USD -3.2%
Nonoperating Income (Expense) 200K USD -45.3%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -1.97M USD -25.3%
Net Income (Loss) Attributable to Parent -9.45M USD -5.18%
Earnings Per Share, Basic -0.76 USD/shares +1.3%
Earnings Per Share, Diluted -0.76 USD/shares +1.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.87M USD -44.5%
Assets, Current 4.04M USD -43.4%
Property, Plant and Equipment, Net 7.37M USD -7.09%
Intangible Assets, Net (Excluding Goodwill) 323K USD -2.5%
Assets 11.7M USD -23.8%
Employee-related Liabilities, Current 46.9K USD +72.8%
Accrued Liabilities, Current 283K USD -16.6%
Liabilities, Current 1.63M USD +72.2%
Liabilities 1.63M USD -33.3%
Retained Earnings (Accumulated Deficit) -143M USD -7.1%
Stockholders' Equity Attributable to Parent 10.1M USD -22.1%
Liabilities and Equity 11.7M USD -23.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.59M USD -121%
Net Cash Provided by (Used in) Financing Activities 1.71M USD
Net Cash Provided by (Used in) Investing Activities -46.8K USD -464%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 14.1M shares +19.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3.87M USD -44.5%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 39.8M USD +6.37%
Deferred Tax Assets, Gross 39.8M USD +6.37%
Depreciation 757K USD +1.65%
Payments to Acquire Property, Plant, and Equipment 46.8K USD +464%
Property, Plant and Equipment, Gross 15M USD +1.32%
Deferred Tax Assets, Operating Loss Carryforwards 29.4M USD +4.98%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 153M USD +4.51%
Amortization of Intangible Assets 2.07K USD 0%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Interest Expense 13.3K USD